Stock Events

Stock Events

Protara Therapeutics 

$4.74
0
+$0+0% Monday 00:03

Statistics

Day High
4.74
Day Low
4.74
52W High
-
52W Low
-
Volume
20
Avg. Volume
-
Mkt Cap
182.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2025
Q4 2025
Next
-0.38
-0.36
-0.33
-0.31
Expected EPS
-0.348571
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-89.19MNet Income

Analyst Ratings

$24.67Average Price Target
The highest estimate is 27.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TARA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences operates in similar therapeutic areas, including oncology, which competes with Protara's cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers a range of oncology treatments that directly compete with Protara's cancer drug pipeline.
Merck
MRK
Mkt Cap214.76B
Merck is known for its strong presence in the oncology market, competing with Protara's cancer therapies.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on innovative treatments in areas like oncology, posing competition to Protara's therapeutic approaches.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad portfolio of oncology drugs that compete with Protara's developments in cancer treatment.
Novartis
NVS
Mkt Cap237.61B
Novartis is a leading pharmaceutical company with a strong emphasis on oncology, competing with Protara's cancer therapies.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a growing oncology segment that competes with Protara's focus on cancer therapeutics.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG, through its Genentech subsidiary, competes in the oncology space, directly challenging Protara's market.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a significant presence in oncology, with a portfolio that competes with Protara's cancer treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its innovative biotechnology, competes in the development of cancer therapies similar to Protara's focus.

About

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Show more...
CEO
ISIN
US74365U1079

Listings

XNAS
US
TARA
F
DE
1KPA.F
BOATS
BOATS
TARA.BOATS

0 Comments

Share your thoughts

FAQ

What is Protara Therapeutics stock price today?▼
The current price of TARA.BOATS is $4.74 USD — it has increased by +0% in the past 24 hours. Watch Protara Therapeutics stock price performance more closely on the chart.
What is Protara Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Protara Therapeutics stocks are traded under the ticker TARA.BOATS.
What is Protara Therapeutics market cap?▼
Today Protara Therapeutics has the market capitalization of 182.9M
When is the next Protara Therapeutics earnings date?▼
Protara Therapeutics is going to release the next earnings report on April 30, 2026.
What were Protara Therapeutics earnings last quarter?▼
TARA.BOATS earnings for the last quarter are -0.37 USD per share, whereas the estimation was -0.31 USD resulting in a -18.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protara Therapeutics revenue for the last year?▼
Protara Therapeutics revenue for the last year amounts to 0 USD.
What is Protara Therapeutics net income for the last year?▼
TARA.BOATS net income for the last year is -89.19M USD.
When did Protara Therapeutics complete a stock split?▼
Protara Therapeutics has not had any recent stock splits.